INBRAIN Neuroelectronics is a spin-off of Graphene Flagship, the Catalan Institute of Nanoscience and Nanotechnology (ICN2) and ICREA, Spain. Since 2019 they have been working on decoding brain signals to design medical solutions for patients with epilepsy, Parkinson’s disease and other neurological disorders, creating small implantable intelligent brain systems that are capable of interpreting brain signals with high fidelity.
The objective is to have a personalized therapeutic response, adapted to each specific patient.
INBRAIN had a significant investment in 2020, and today announces a Series A investment of 14.35M, one of the largest rounds in MedTech’s Spanish industry.
With this investment, they will be able to bring the technology to humans using a nanoscale graphene electrode, innovating in a technology that currently relies mainly on metals such as platinum and iridium, which impose significant restrictions in terms of miniaturization and resolution of the signal and, therefore, they cause considerable side effects.
Current technology has a rejection rate of 50%, but technology based on the use of graphene improves that number by not relying on metals.
Thanks to nanoscale manufacturing, they will be able to achieve the resolution of a single neuron. Being much smaller, they are safer to deploy, but can also be programmed, updated and recharged wirelessly.
Powered by artificial intelligence, the implant can learn from each specific patient’s brain and trigger adaptive responses to deliver personalized neurological therapy. In addition, the use of big data management will allow remote device monitoring and data processing.
So far, studies have already been conducted in large animals, and the investment will bring the technology to human patients, in collaboration with key neurological and neurosurgical groups in Europe.
You can get more information at inbrain-neuroelectronics.com
